Arcellx, INC Form 4 insider transactions

Arcellx's Chief Medical Officer, Christopher Heery, executed multiple stock transactions, including the sale of shares to cover tax obligations related to vested restricted stock units.

Arcellx's Chief Financial Officer, Michelle Gilson, executed multiple transactions involving the company's common stock, including the sale of shares to cover tax obligations related to vested restricted stock units.

Arcellx Inc. executive Rami Elghandour reported the acquisition of shares through restricted stock units and subsequent sales to cover tax obligations.

Arcellx's Chief Financial Officer, Michelle Gilson, reported multiple transactions involving the company's stock, including the vesting and sale of restricted stock units.

Arcellx's Chief Medical Officer, Christopher Heery, reported the acquisition of shares through restricted stock unit vesting and subsequent sales to cover tax obligations.

Arcellx's Chief Medical Officer, Christopher Heery, reported the acquisition of shares through restricted stock unit vesting and subsequent sales to cover tax obligations.

Arcellx director Rami Elghandour acquired and disposed of company stock, including through the vesting of restricted stock units, and granted a power of attorney for SEC filings.

Arcellx director Kavita Patel exercised stock options and sold shares on December 24, 2024, under a pre-arranged 10b5-1 trading plan.

Arcellx director Kavita Patel exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan on December 3, 2024.

Arcellx's Chief Financial Officer, Michelle Gilson, sold shares and exercised stock options, according to a recent SEC filing.

Arcellx director Kavita Patel exercised stock options and sold shares on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Arcellx's Chief Financial Officer, Michelle Gilson, executed multiple stock transactions, including both option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Arcellx director Kavita Patel exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. under a pre-arranged 10b5-1 trading plan.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. on October 1, 2024, according to a Form 4 filing.

Arcellx's CFO, Michelle Gilson, exercised stock options and sold shares of common stock on September 17, 2024, according to a recent SEC filing.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., exercised stock options and sold shares on September 5, 2024, according to a Form 4 filing with the SEC.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports exercising stock options and selling shares of common stock on September 3, 2024, according to a Form 4 filing with the SEC.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., exercised stock options and sold shares of common stock on August 26, 2024, according to a Form 4 filing with the SEC.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., exercised a stock option and sold shares of common stock on August 16, 2024, according to a Form 4 filing with the SEC.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports the acquisition and disposal of common stock and derivative securities, including stock options, on August 1, 2024.

Director Kavita Patel exercised stock options and sold Arcellx shares under a pre-arranged Rule 10b5-1 trading plan.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., exercised stock options and sold shares on July 16, 2024, according to a recent SEC filing.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., exercised stock options and sold shares of common stock on July 11 and 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. on July 9, 2024, according to a Form 4 filing with the SEC.

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports the acquisition and disposal of common stock and derivative securities, including stock options, on July 1, 2024, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Director Kavita Patel exercised stock options and sold shares of Arcellx, Inc. on June 27, 2024, according to a Form 4 filing with the SEC.

Michelle Gilson, CFO of Arcellx, Inc., sold shares of common stock on June 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.